Business Context and Reporting Period
This Form 8-K was filed by Actinium Pharmaceuticals, Inc. on June 7, 2019, reporting events occurring as of that date. The filing addresses the Company's compliance status with NYSE American listing requirements regarding stockholders' equity.
Key Financial Metrics
- Stockholders' Equity: Below $6 million as of March 31, 2019; increased to above $6 million following a capital raise in April 2019.
- Financing Proceeds: Gross proceeds of $16.5 million; net proceeds of $15.1 million after expenses.
- Capital Raised: $15.1 million added to stockholders' equity.
- Profitability: The Company has incurred losses in its five most recent fiscal years.
Material Changes
The primary material change is the restoration of compliance with NYSE American listing standards. As of March 31, 2019, the Company failed to meet the minimum $6 million stockholders' equity requirement due to cumulative losses. This deficiency was resolved in April 2019 through a public offering, raising stockholders' equity above the required threshold.
Outlook, Risks, and Unusual Items
Capital Raise Details: The Company sold 42.9 million shares of common stock at $0.385 per share. Additionally, warrants were issued to purchase up to 42.9 million shares at an exercise price of $0.50 per share with a 5-year term.
Risk Factors: The filing highlights the risk of delisting due to insufficient equity, which was mitigated by the April 2019 financing. The Company's history of losses over the last five fiscal years remains a significant operational context.
Investor Verification Checklist
- Verify the current stockholders' equity balance in the most recent Form 10-Q filed on May 10, 2019.
- Confirm the dilution impact of the 42.9 million new shares and associated warrants.
- Review the Company's cash burn rate and runway given the history of losses.
- Check for any subsequent filings regarding the use of the $15.1 million in net proceeds.